LLY vs RADX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
RADX presents a high-risk profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation benchmarks like the Graham Number due to negative earnings. While the company shows impressive YoY revenue growth of 154.50% and maintains strong short-term liquidity (Current Ratio 3.01), these are overshadowed by a catastrophic negative gross margin of -136.51%. The stock is in a severe technical downtrend, having collapsed from a 52-week high of $16.25 to $4.58, suggesting a significant loss of investor confidence despite optimistic analyst price targets.
Compare Another Pair
Related Comparisons
LLY vs RADX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Radiopharm Theranostics Limited (RADX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.